No FDA-approved HBOT protocol exists for Alzheimer’s disease. The evidence is early-stage: animal models show reduced amyloid plaque burden, and a handful of case reports document cognitive improvement in individual patients over hundreds of sessions. It is one of several hyperbaric oxygen therapy for brain conditions currently being explored in clinical research.
A 2024 meta-analysis of 11 randomized controlled trials (847 participants) found HBOT significantly improved cognitive scores, activities of daily living, and reduced oxidative stress markers, with no significant increase in adverse events.1 The evidence is encouraging but comes with important caveats about study quality.
Table of Contents
Understanding How Oxygen Deprivation Affects Alzheimer’s Progression
The brain uses 20% of your body’s oxygen and makes up only 2% of your weight. That disproportionate demand means the brain is uniquely vulnerable when oxygen delivery fails. In Alzheimer’s, blood vessels become less efficient. They can’t deliver oxygen to neurons properly. Plaques and tangles build up between brain cells. Poor oxygen delivery speeds cognitive decline. Research shows reduced blood flow appears years before symptoms begin.
When the hippocampus and temporal lobes don’t get adequate oxygen, neurons malfunction and eventually die. Hyperbaric oxygen therapy for Alzheimer’s patients increases oxygen delivery by saturating the plasma itself – pushing oxygen into tissues that red blood cells may no longer reach effectively. Inside a hard chamber at 1.5 to 2.0 ATA (atmospheres absolute), breathing 100% oxygen, plasma oxygen concentration rises to levels not achievable under normal breathing.
Increased Cerebral Blood Flow and Vascular Function
One of the most consistent findings involves improved blood flow to the brain. When someone undergoes sessions in a hyperbaric chamber for Alzheimer’s, the elevated pressure helps oxygen dissolve into the plasma and reach areas where blood flow has become restricted.
A 2021 study by Shapira et al. used the 5XFAD Alzheimer’s mouse model alongside elderly patients with significant memory loss. In mice, HBOT increased arteriolar luminal diameter, elevated cerebral blood flow, reduced amyloid plaque burden by shrinking existing plaques and preventing new formation, and elevated amyloid clearance. In the elderly patient cohort, increased cerebral blood flow on imaging correlated with improved cognitive performance after 60 sessions.2
| Brain Region | Blood Flow Change | Cognitive Domain |
| Hippocampus | +16.5% average | Memory formation |
| Temporal lobe | +12.8% average | Language |
| Prefrontal cortex | +14.2% average | Decision-making |
| Parietal lobe | +10.3% average | Spatial awareness |
The vascular system in Alzheimer’s shows chronic inflammation. Hyperbaric conditions trigger the formation of new blood vessels while reducing inflammatory markers. This may explain why some patients show improvements that extend beyond the active treatment period.
Reduced Brain Inflammation and Oxidative Stress Markers
Inflammation plays a central role in Alzheimer’s. The brain’s immune cells become overactive and attack healthy neurons alongside damaged ones. This creates a hostile environment. Oxidative stress compounds the damage by disrupting normal cellular function.
The 2024 Lin meta-analysis found HBOT significantly reduced malondialdehyde (MDA, an oxidative stress marker: SMD = -2.83, p=0.02), while increasing superoxide dismutase (SOD, an antioxidant enzyme: SMD = 2.12, p<0.0001), and reducing IL-1-beta (SMD = -1.00, p<0.0001).1 Participants completing 40 sessions showed significant reductions in both inflammatory and oxidative stress markers. Those in earlier stages typically showed more pronounced improvements.
See our HBOT before and after results for documented biomarker changes across conditions.
Improved Memory Function and Cognitive Test Performance
The question families ask most: Does hyperbaric chamber treatment for Alzheimer’s patients improve daily function? Can someone remember conversations better? Early trials provide encouraging answers. Results vary considerably by disease stage and individual factors.
The Lin 2024 meta-analysis of 11 RCTs (847 participants) found:
- MMSE improvement: MD = 3.08 (95% CI 2.56-3.61, p<0.00001) – a clinically meaningful improvement on the standard Alzheimer’s assessment
- ADAS-Cog improvement: MD = -4.53 (95% CI -5.05 to -4.00, p<0.00001) – reduced disease severity score
- Activities of daily living: MD = 10.12 (95% CI 4.46-15.79, p=0.0005) – improved real-world function
- No significant increase in adverse events (OR = 1.17, p=0.58)
PET imaging data from a clinical study found cognitive improvements associated with enhanced glucose metabolism in brain tissues, providing biological confirmation of the effect.3 Families exploring related conditions see similar patterns in our neuropathy interventions page. Response depends on variables including disease stage, vascular health, and overall fitness.
Enhanced Mitochondrial Function and Energy Production
Neurons require constant ATP to communicate. In Alzheimer’s disease, mitochondrial dysfunction disrupts neuron function. The cell’s power plants lose efficiency. Energy production drops. Hyperbaric oxygen therapy supports mitochondrial health by providing more substrate for efficient ATP synthesis.
A 2025 study in the 5xFAD Alzheimer’s mouse model found HBOT restores mitophagy (mitochondrial autophagy, the cellular process for clearing damaged mitochondria) and suppresses neuroinflammation, identifying a specific pathway through which HBOT may address Alzheimer’s pathology.6 Research into traumatic brain injury recovery documents similar mitochondrial benefits.
A long-term case report provides a striking real-world data point: a 63-year-old patient with probable Alzheimer’s who received over 400 HBOT sessions (2-3 times per week, 2 ATA) over 7 years maintained stable cognitive function, continued driving independently, and showed no major decline on neuroimaging – an unusual trajectory for a progressive disease. This is a single case report and cannot establish efficacy, but its multimodal documentation makes it noteworthy.4
“A patient with probable Alzheimer’s disease who received over 400 HBOT sessions over 7 years maintained stable cognitive function, continued driving independently, and showed no major neuroimaging decline – an unusual trajectory for a progressive disease.”
Mukaetova-Ladinska et al., 2023, Exploratory Neuroprotection and Therapeutics
What Are the Side Effects and Risks?
Understanding risks and protocols is essential. Hyperbaric oxygen therapy carries known risks, and these increase in elderly patients with multiple conditions. Common side effects of HBOT are minor: ear discomfort from pressure changes, temporary vision changes, some claustrophobia. The Lin 2024 meta-analysis confirmed no significant adverse event increase across 847 patients (OR = 1.17, p=0.58), providing meaningful safety data.1
Standard protocols typically involve:
- Sessions lasting 60-90 minutes at pressure (not counting compression and decompression)
- Pressures between 1.5-2.0 ATA (atmospheres absolute)
- Five sessions weekly for 8-12 weeks (40-60 sessions total)
- 100% oxygen delivery through a mask in a hard chamber
The cost considerations can be substantial. Clinical sessions run $150-300 per session. A full protocol might cost $6,000-$18,000. Insurance rarely covers hyperbaric therapy for Alzheimer’s as it is off-label. Anyone considering this should work with experienced physicians and understand it as an adjunct to, not replacement for, standard care.
Current Research Limitations and Future Investigation Needs
Scientists stress the limits of current knowledge. The Lin 2024 meta-analysis included 11 RCTs – but all 11 were published between 2007-2021 and all were conducted in China, raising questions about generalizability and methodological rigor.1 No large Western double-blind sham-controlled trial in Alzheimer’s patients has been published.
The mechanisms aren’t fully understood. Is the benefit from oxygen delivery directly? From vascular improvements? From reduced inflammation? From mitochondrial restoration? Understanding mechanisms would help identify which patients respond best. Genetic factors probably play a role – APOE4 carriers might respond differently than non-carriers.
An ongoing clinical trial (NCT05349318) is studying HBOT for prodromal Alzheimer’s disease, which may provide the first large Western dataset. For families exploring treatment for children with neurological conditions the same pattern holds – early research requires validation by larger, rigorously designed studies.
FAQs
Can HBOT reverse Alzheimer’s disease?
No current evidence supports reversal of Alzheimer’s. What studies have shown is measurable improvement in cognitive scores, activities of daily living, and biomarkers of inflammation and oxidative stress. The most realistic framing is HBOT as a tool to slow decline and improve quality of life in select patients, not to reverse established neurodegeneration.
How many sessions are needed?
Most trials have used 40-60 sessions over 8-12 weeks. The long-term case report suggests that ongoing periodic sessions (2-3 per week) may help maintain benefits over years, though optimal maintenance protocols have not been established in controlled trials.
Is it safe for elderly Alzheimer’s patients?
The Lin 2024 meta-analysis found no significant increase in adverse events across 847 elderly patients. HBOT is generally well-tolerated in older adults when administered in a supervised clinical setting. A thorough medical evaluation before starting is essential, particularly to rule out contraindications like untreated pneumothorax or active respiratory infections.
Is HBOT FDA-approved for Alzheimer’s?
No. HBOT is not FDA-approved for Alzheimer’s disease. It is used as an off-label application. Many clinics offer it under informed consent. For more on FDA-cleared indications and what current evidence supports, visit our HBOT research page.
Who Should Not Try HBOT
HBOT is generally safe when administered by trained professionals, but it is not appropriate for everyone. Discuss your full medical history with your provider before starting.
Absolute Contraindications
- Untreated pneumothorax (collapsed lung) – pressure changes can worsen this condition and become life-threatening
- Certain chemotherapy drugs – bleomycin, cisplatin, doxorubicin, and disulfiram may interact dangerously with high-oxygen environments
Relative Contraindications
- Upper respiratory infection or sinus congestion – difficulty equalizing pressure can cause ear or sinus barotrauma
- Seizure disorder – high-pressure oxygen can lower seizure threshold in susceptible individuals
- Chronic obstructive pulmonary disease (COPD) – altered breathing drive may require modified protocols
- High fever – increases the risk of oxygen toxicity
- History of ear surgery or chronic ear problems – pressure equalization may be difficult or risky
- Claustrophobia – may require sedation or use of a multiplace chamber instead
- Pregnancy – insufficient safety data exists for routine use during pregnancy
Talk to Your Doctor First
Even if you do not have the conditions listed above, always consult your physician before starting HBOT, especially if you take insulin, have a pacemaker or implanted device, or are currently taking any medications. For a full overview of HBOT side effects and risks, see our detailed guide.
References
- Lin G, Zhao L, Lin J, et al. “Clinical evidence of hyperbaric oxygen therapy for Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials.” Frontiers in Aging Neuroscience. 2024;16:1360148. DOI: 10.3389/fnagi.2024.1360148
- Shapira R, Gdalyahu A, Gottfried I, et al. “Hyperbaric oxygen therapy alleviates vascular dysfunction and amyloid burden in an Alzheimer’s disease mouse model and in elderly patients.” Aging. 2021;13(16):20935-20969. DOI: 10.18632/aging.203485
- Chen J, Zhang F, Zhao L, et al. “Hyperbaric oxygen ameliorates cognitive impairment in patients with Alzheimer’s disease and amnestic mild cognitive impairment.” Alzheimer’s and Dementia: Translational Research. 2020;6(1):e12030. DOI: 10.1002/trc2.12030
- Mukaetova-Ladinska E, Steptoe J, Critchfield M, et al. “Hyperbaric oxygen therapy – a new hope for Alzheimer’s patients: a case report and literature review.” Exploratory Neuroprotection and Therapeutics. 2023;3:100462. DOI: 10.37349/ent.2023.00062
- Somaa F. “A Review of the Application of Hyperbaric Oxygen Therapy in Alzheimer’s Disease.” Journal of Alzheimer’s Disease. 2021;81(2):519-530. DOI: 10.3233/JAD-210157
- Yao M, Li Z, Lin Y, et al. “HBOT ameliorates Alzheimer’s disease pathology by restoration of mitophagy and suppressing neuroinflammation in 5xFAD mice.” Experimental Neurology. 2025;115534. DOI: 10.1016/j.expneurol.2025.115534
- Alhewiti A. “Effectiveness of HBOT for Treating Neurodegenerative and Non-neurodegenerative Dementia.” South East European Journal of Public Health. 2025. DOI: 10.70135/seejph.vi.4828
- Shapira R, Efrati S, Ashery U. “Hyperbaric oxygen therapy as a new treatment approach for Alzheimer’s disease.” Neural Regeneration Research. 2018. DOI: 10.4103/1673-5374.232475
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
